These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25136028)

  • 1. Tedizolid population pharmacokinetics, exposure response, and target attainment.
    Flanagan S; Passarell J; Lu Q; Fiedler-Kelly J; Ludwig E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6462-70. PubMed ID: 25136028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.
    Lepak AJ; Marchillo K; Pichereau S; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5916-22. PubMed ID: 22964254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
    Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
    Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
    Flanagan S; Minassian SL; Morris D; Ponnuraj R; Marbury TC; Alcorn HW; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6471-6. PubMed ID: 25136024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections.
    Li D; Sabato PE; Guiastrennec B; Ouerdani A; Feng HP; Duval V; De Anda CS; Sears PS; Chou MZ; Hardalo C; Broyde N; Rizk ML
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0089521. PubMed ID: 34516243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.
    Housman ST; Pope JS; Russomanno J; Salerno E; Shore E; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 May; 56(5):2627-34. PubMed ID: 22330925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
    Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections.
    Carena AA; Stryjewski ME
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):577-592. PubMed ID: 32449440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
    McCool R; Gould IM; Eales J; Barata T; Arber M; Fleetwood K; Glanville J; Kauf TL
    BMC Infect Dis; 2017 Jan; 17(1):39. PubMed ID: 28061827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.
    Prokocimer P; Bien P; Surber J; Mehra P; DeAnda C; Bulitta JB; Corey GR
    Antimicrob Agents Chemother; 2011 Feb; 55(2):583-92. PubMed ID: 21115795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
    Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
    J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis.
    Park AYJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.
    Burdette SD; Trotman R
    Clin Infect Dis; 2015 Oct; 61(8):1315-21. PubMed ID: 26105167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.
    McBride D; Krekel T; Hsueh K; Durkin MJ
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):331-337. PubMed ID: 28140693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
    Rybak JM; Marx K; Martin CA
    Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
    Lv X; Alder J; Li L; O'Riordan W; Rybak MJ; Ye H; Zhang R; Zhang Z; Zhu X; Wilcox MH
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis.
    Park KH; Greenwood-Quaintance KE; Mandrekar J; Patel R
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6568-6572. PubMed ID: 27550347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents.
    Bradley JS; Flanagan SD; Arrieta AC; Jacobs R; Capparelli E; Prokocimer P
    Pediatr Infect Dis J; 2016 Jun; 35(6):628-33. PubMed ID: 26910588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
    Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
    Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.